Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo

Cancer Science

Volumn 94, Issue 2, 2003, Pages 200-204

  Morinaga, Yoshihiro ^a   Suga, Yasuyo ^a   Ehara, Sumiko ^a   Harada, Katsuhiro ^a   Nihei, Yukio ^a   Suzuki, Manabu ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMBRETASTATIN A4; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; VINDESINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CISPLATIN; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED ICR; MICE, NUDE; SARCOMA 180; SERINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038297388     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01419.x     Document Type: Article

References (21)

1. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garia-Kandall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia 1989; 45: 205-11.
2. El-Zayar AAE, Degen D, Drabek S, Clark GM, Pettit GR, von Hoff DD. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 1993; 4: 19-25.
3. Ohsumi K, Nakagawa R, Fukuda Y, Hatanaka T, Morinaga Y, Nihei Y, Ohishi K, Suga Y, Akiyama Y, Tsuji T. Novel combretastatin analogues effective against marine solid tumors: design and structure-activity relationships. J Med Chem 1998; 41: 3022-32.
4. Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T. A novel conbretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999; 90: 1016-25.
5. Hori K, Saito S, Nihei M, Suzuki M, Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC-7700. Jpn J Cancer Res 1999; 90: 1026-38.
6. Nihei Y, Suzuki M, Okano, A, Akiyama Y, Hori K, Saito S, Sato Y. Anti-vascular effects of AC-7700 on solid tumors; comparison with other tubulin binding agents. Proc Am Assoc Cancer Res 1998; 39: 167.
7. Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 1985; 69: 945-51.
8. Johnson BE, Salem C, Nesbitt J. Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin. Lung Cancer 1993; 9: 215-65.
9. Belinson JL, McClure M, Ashikaga T, Krakoff IH. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin. Cancer 1984; 54: 1983-90.
10. Bonomi P, Kim K, Kusler J, Johnson D. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Huntingt) 1997; 11: 9-10.
11. Wozniak AJ, Crowly JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor, SA, Gandara DR, Livingston RB. J Clin Oncol 1998; 16: 2459-65.
12. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90-6.
13. Wood SA, Vlassopoulos D, Mucci A. Effects of concentrated matrices on the determination of traces of platinum and gold in aqueous samples using solvent extraction-Zeeman effect graphite furnace atomic absorption spectrometry and inductively coupled plasma-mass spectrometry. Anal Chim Acta 1990; 229: 227-38.
14. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastinc, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 1976; 36: 3798-802.
15. Lee K, Tanaka M, Kanamaru H, Hashimura T, Yamamoto I, Konishi J, Kuse F. In vitro antagonism between cisplatin and vinca alkaloids. Br J Cancer 1989; 59: 36-41.
16. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloid: anti-vascular effects in a mutine tumour. Ear J Cancer 1993; 29A: 1320-4.
17. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumor therapy: evaluation of tubulin binding agents. Br J. Cancer 1996; 74 Suppl 27: S86-S88.
18. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 1988; 21: 185-90.
19. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189-96.
20. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002; 41: 91-7.
21. Siernann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99: 1-6.